Ifosfamide in advanced/disseminated breast cancer

R. Sorio, D. Lombardi, S. Spazzapan, N. La Mura, G. Tabaro, A. Veronesi

Research output: Contribution to journalArticlepeer-review


Ifosfamide is an alkylating agent active in various tumor types including breast cancer. The availability of mesna (sodium 2-mercaptoethanesulfonate) has increased its safety, avoiding the main dose-limiting side effect, urotoxicity. Interesting activity as a single agent, with response rates ranging from 7 to 30%, is reported in pretreated patients; more attractive data derived from phase II studies on ifosfamide combined with drugs known to be active in advanced breast cancer show response rates always over 35%. This review has taken in consideration papers published after 1995 and available on PubMed medline: the data indicate a potential usefulness of ifosfamide in the clinical management of advanced breast cancer, even if the exact therapeutic role of the drug in this setting should be derived from randomized studies not yet available.

Original languageEnglish
Pages (from-to)55-58
Number of pages4
Issue numberSUPPL. 2
Publication statusPublished - 2003


  • Breast cancer
  • Ifosfamide
  • Mesna
  • Urotoxicity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Ifosfamide in advanced/disseminated breast cancer'. Together they form a unique fingerprint.

Cite this